IP Library Granted Patent US 9,255,111
Granted Patent B2
US 9,255,111 · App. 14/546,590 · Granted Feb 9, 2016

Parasiticidal dihydroisoxazole compounds

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,255,111
App. No.
14/546,590
Granted
Feb 9, 2016
Kind
B2
Abstract

Provided are dihydroisoxazole compounds I useful for controlling parasites both in animals and agriculture. Further provided are methods for controlling parasite infestations of an animal by administering an effective amount of a compound as described above, or a pharmaceutically acceptable salt thereof, to an animal, as well as formulations for controlling parasite infestations using the compounds described above or an acceptable salt thereof, and an acceptable carrier. Also provided are compounds and processes useful for making the dihydroisoxazole compounds. wherein A is

Claims (20)

1. A compound of formula I, or salt thereof:

2. The compound, or salt thereof, of claim 1 , wherein the compound is (S)-3-[5-(3,5-dichloro-4-fluoro-phenyl)-5-trifluoromethyl-4,5-dihydro-isoxazol-3-yl]-5,6-dihydro-4H-cyclopenta[c]thiophene-1-carboxylic acid [(2,2-difluoro-ethylcarbamoyl)-methyl]-amide.

3. A formulation comprising the compound, or salt thereof, of claim 1 and one or more acceptable carrier.

4. The formulation of claim 3 , wherein the one or more acceptable carrier comprises a pharmaceutically acceptable or a veterinary acceptable carrier.

5. The formulation of claim 4 , wherein the formulation is a human pharmaceutical formulation.

6. The formulation of claim 4 , wherein the formulation is a veterinary pharmaceutical formulation.

7. The formulation of claim 3 , further comprising at least one additional active ingredient.

8. The formulation of claim 3 , wherein the formulation is an oral dosage formulation.

9. The formulation of claim 3 , wherein the formulation is a parenteral dosage formulation.

10. The formulation of claim 3 , wherein the formulation is a topical dosage formulation.

11. A method of controlling a parasite infestation in or on an animal in need thereof comprising administering an effective amount of the compound, or salt thereof, of claim 1 to said animal.

12. The method of claim 11 , wherein said animal is a human.

13. The method of claim 11 , wherein said animal is a companion animal.

14. The method of claim 13 , wherein said companion animal is a dog or cat.

15. The method of claim 11 , wherein said animal is a livestock animal.

16. The method of claim 11 , wherein said parasite is a flea, tick, or mite.

17. The method of claim 11 , wherein at least one other active ingredient is administered to said animal.

18. A method for treating an animal for a parasite infestation or for a disease transmitted thorough parasites, comprising administering to an animal in need of treatment the compound, or salt thereof, of claim 1 in an amount effective to treat the animal.

19. The method of claim 18 , wherein administering the compound comprises topically, orally, or parenterally administering the compound to the animal.

20. The method of claim 18 , further comprising administering at least one other active ingredient to the animal.

Assignments (3)
ASSIGNMENT OF SECURITY INTEREST IN PATENT RIGHTS, RECORDED ON AUGUST 3, 2020, AT REEL/FRAME 053388/0967 Recorded Dec 3, 2025
From: GOLDMAN SACHS BANK USA, AS RETIRING COLLATERAL AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR COLLATERAL AGENT
Reel/Frame 073816/0021 →
SECURITY INTEREST Recorded Aug 3, 2020
From: ELANCO US INC.
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 053388/0967 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2018
From: ELI LILLY AND COMPANY
To: ELANCO US INC.
Reel/Frame 044701/0538 →